Dennis Hofmann
Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com
Share
Services
Investors
New strategy and clear focus
Fresenius has hit RESET and is now moving towards #FutureFresenius with a simplified structure, sharper focus and acceleration of performance
Intention to deconsolidate Fresenius Medical Care by changing the legal form of FMC to a German Stock Corporation (“Aktiengesellschaft”) in simplified governance
Focus on Operating Companies Fresenius Kabi and Fresenius Helios
Active portfolio management for assets where Fresenius lacks best ownership
New, more rigorous Fresenius Financial Framework with ambitious segment margin bands
~€1bn annual structural productivity improvement by 2025
“We are keeping a quick and consistent pace in implementing our #FutureFresenius program. And the effects are becoming tangible. Our Operating Companies, Fresenius Helios and Fresenius Kabi, have top market positions, and are bringing innovations to patients every day. Both delivered solid second quarter results, including stronger than expected revenue growth. Both are within their respective margin bands, which we established earlier this year as part of our new financial framework...”
We are committed to being a socially and environmentally responsible corporate player in the global healthcare market. We have the ambition to shape future healthcare and build a sound base for sustainable growth.
mAbxience, a Fresenius Kabi majority-owned Group, today announced a strategic partnership with Abbott to commercialize several biosimilars focusing on oncology, women’s health and respiratory diseases in emerging markets including Latin America, Southeast Asia, the Middle East, and Africa. The first molecules are expected to be launched in 2025. mAbxience will manufacture the biosimilars in its state-of-the art and Good Manufacturing Practices (GMP)-approved facilities in Spain and Argentina. Additionally, mAbxience will be responsible for driving the clinical milestones for some of the molecules still undergoing development. The biosimilars will be commercialized by Abbott.
This strategic partnership strengthens mAbxience’s global presence and expands access to cutting-edge healthcare solutions in underserved regions.
September 20, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
The European Commission (EC) has approved Fresenius Kabi’s tocilizumab biosimilar Tyenne®*. It is the first tocilizumab biosimilar approved by the EC and Fresenius Kabi’s third approved biosimilar in Europe. This approval is another crucial milestone in the company’s Vision 2026 growth strategy.
* Tyenne® (tocilizumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
September 19, 2023 · Fresenius Kabi
Brief News
Key parameter for the 2024 DRG inflator for German hospitals set at 4.22%
The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2024 in Germany, has been set at 4.22%. Due to cost inflation, the rate of change will most likely mark the lower limit of the price increase for hospital treatments for 2024 in Germany. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.
September 18, 2023 · Fresenius Helios
Brief News
Fresenius Kabi signed an agreement with Virginia Oncology Associates to deliver Ivenix Infusion System
Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients. VOA specializes in treating people with cancer and blood disorders. It is part of the national US Oncology network.
Fresenius Kabi and VOA have agreed to work together to integrate the Ivenix Infusion System with VOA’s electronic medical record (EMR) system.
Fresenius appoints Robert Möller to the Management Board
The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect. At the same time, he will take over as Chairman of the Management Board of Helios Health GmbH. He succeeds Dr. Francesco de Meo (59), who will leave the company.
September 08, 2023 · Fresenius
Brief News
Progress on #FutureFresenius: Fitch revises the outlook of Fresenius SE & Co. KGaA from negative to stable, rating affirmed at BBB-
The rating agency Fitch today revised the outlook of Fresenius from negative to stable. The rating was affirmed at BBB-. The improved outlook is based on the consistent performance of the Operating Companies, a prudent capital allocation and progress on the group simplification, amongst others. The revised outlook is another strong testament of the successful execution of the strategy towards #FutureFresenius. Fresenius remains committed to its investment grade rating and its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA.
August 25, 2023 · Fresenius
Brief News
Fresenius Kabi launches two generic drugs in the U.S.
Fresenius Kabi today announced the immediate availability of two drugs in the United States. The first product, Gadobutrol Injection, a gadolinium-based contrast agent for used in MRIs.1 It is the latest addition to Fresenius Kabi’s new radiology portfolio that offers hospitals a range of cost-effective contrast agents. The second product, Plerixafor Injection, a hematopoietic stem cell mobilizer is the newest addition to the company’s large generic injectable oncology medicine portfolio.
1 Gadobutrol Injection Package Insert, January 2023
August 09, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi and Formycon secure U.S. License Date for Ustekinumab biosimilar candidate
Fresenius Kabi and Formycon have entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed Ustekinumab biosimilar in the United States. Subject to regulatory approval, the settlement grants an entry date for FYB202 in the United States no later than April 15, 2025.
FYB202 is an Ustekinumab biosimilar candidate that references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.
* Stelara® is a registered trademark of Johnson & Johnson
Progress on #FutureFresenius: Operating Companies showing consistent performance; Group simplification delivered
August 02, 2023 · Fresenius
Brief News
Fresenius Kabi’s tocilizumab biosimilar receives positive opinion on Marketing Authorization Application (MAA) for Europe
Fresenius Kabi’s tocilizumab biosimilar candidate, MSB11456, has received a positive recommendation for a marketing authorization from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). MSB11456 becomes the first tocilizumab biosimilar candidate to be granted a positive opinion by the CHMP for the treatment of several autoimmune diseases. This achievement marks a significant milestone in Fresenius Kabi’s Vision 2026 growth strategy.
For more information, please see the website of Fresenius Kabi.
Fresenius Kabi announced today that its biosimilar candidate FKS518, a denosumab biosimilar candidate for the US reference product Prolia®*, successfully met its primary and secondary objectives in a recently conducted clinical trial on pharmacokinetic similarity. For more information, please see the website of Fresenius Kabi.
*Prolia® is a registered trademark of Amgen Inc.
July 12, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi launches two generic drugs in the U.S.
Fresenius Kabi today announced the immediate availability of two drugs in the United States. The first product, Ganirelix Acetate Injection, a generic fertility drug is part of the company’s expansion in women’s health. Ganirelix Acetate Injection is indicated for the inhibition of premature surges in luteinizing hormone, a chemical in the body that triggers reproductive processes such as ovulation. The second product is fentanyl citrate in a Simplist® ready-to-administer prefilled syringe presentation. The product is the only 100 mcg per 2 mL presentation available on the U.S. market in a manufacturer-prepared prefilled syringe.
July 11, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi launches its biosimilar adalimumab Idacio in the U.S.
Fresenius Kabi announced today the launch of its citrate-free biosimilar Idacio®* (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases, in the U.S. Idacio® (adalimumab-aacf) is a tumor necrosis factor (TNF) blocker and a biosimilar to Humira®** (adalimumab). Idacio® is Fresenius Kabi’s second biosimilar launched in the U.S. and another key milestone in the company’s Vision 2026 growth strategy to broaden its biopharma global reach.
* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc.
Fresenius announces changes in the Management Board
Dr. Ernst Wastler will leave the Fresenius Management Board upon reaching retirement age on July 18, 2023
Changes and rejuvenation in the Management team of the Fresenius Vamed business segment
Strengthened control function through new appointments in the reduced VAMED Supervisory Board and the establishment of an Audit Committee
Following successful deconsolidation, Fresenius Medical Care will also no longer be represented on the Fresenius Board in future
The composition of the Board reflects realignment through #FutureFresenius
The healthcare group Fresenius will have a revised Management team going forward. Dr. Ernst Wastler, previously responsible for Fresenius Vamed, will retire as Chairman of the VAMED Management Board and consequently from the Fresenius Management Board upon reaching retirement age on July 18, 2023. Dr. Klaus Schuster and Frank-Michael Frede will be appointed to the VAMED Management Board. Dr. Klaus Schuster will assume the new role of Spokesman of the VAMED Management Board but will not be represented on the Fresenius Management Board. Dr. Michael Moser, a new member of the Fresenius Management Board, will be responsible for Fresenius Vamed within the Fresenius Board.
Following the successful deconsolidation of Fresenius Medical Care, Helen Giza will also step down from the Fresenius Management Board. The #FutureFresenius strategy, with its realignment of business segments into operating and investment companies, is also reflected in the composition of the Fresenius Management Board.
"I would like to thank Dr. Wastler for his many years of highly dedicated work on the Fresenius Board," said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. "The leaner Fresenius Board in the future also takes into account the changes on the path to #FutureFresenius that Michael Sen and the Management Board team are successfully and consistently driving forward."
Dr. Klaus Schuster joined VAMED Management and Service GmbH as Chief Operating Officer (COO) in 2020. Schuster is a medical doctor and worked as a physician at Landesklinikum St. Pölten for ten years. He studied and obtained his doctorate at the Medical University of Vienna and holds an MBA in Health Care Administration from Danube University Krems.
Also appointed to the VAMED Board as of July 1, 2023, is Frank-Michael Frede, CEO of VAMED Deutschland Holding since 2022.
Gottfried Koos' (67) tenure on the VAMED Board will end on June 30, 2023. The four-member VAMED Board will continue to include the two current members, Andrea Raffaseder and Andreas Wortmann. Andreas Wortmann, Chief Financial Officer, will additionally take on the newly created role of Chief Transformation Officer.
Strengthened control function
The control function of the VAMED Supervisory Board will be strengthened. Firstly, it will be reduced from eight to six members. Commercial Councillor Karl Samstag, previously Deputy Chairman of the VAMED AG Supervisory Board and retired CEO of Austria Creditanstalt AG, as well as Dr. Robert Hink, former Secretary General of the Austrian Association of Municipalities, will resign from their positions with effect from the date of the next ordinary Supervisory Board meeting on July 12, 2023.
Dr. Dieter Schenk, Deputy Chairman of the Supervisory Board of Fresenius Management SE, will continue to lead the VAMED Supervisory Board. Sara Hennicken, CFO of Fresenius and a member of the VAMED Supervisory Board since December 2022, will remain a member of this Board and is due to be elected Deputy Chairman. Andreas Schmidradner, Advisor to the Management Board of B&C Industrieholding GmbH, will also continue to be a member of the Supervisory Board. Dr. Michael Moser, a future member of the Fresenius Management Board, was newly elected to the VAMED Supervisory Board with effect from July 12, 2023. Together with two employee representatives, Sara Hennicken, Dr. Dieter Schenk, Andreas Schmidradner and Dr. Michael Moser will form the six-member VAMED Supervisory Board going forward. Additionally, an Audit Committee consisting of Sara Hennicken as Chair, Michael Moser as Deputy Chair, and potentially one employee representative will be established.
June 28, 2023 · Fresenius
Brief News
Fresenius Kabi expands its critical care portfolio in the U.S.
Fresenius Kabi expands its portfolio of critical care medicines by launching Vasopressin Injection, USP, a generic equivalent to Vasostrict®* in the U.S.
Fresenius Kabi Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
* Vasostrict® is a registered trademark of Par Pharmaceutical.
Fresenius executing on #FutureFresenius: Strong performance of Operating Companies in Q1/23 and structural simplification on track
“With a simplified Group structure, improved performance, and a clear focus, Fresenius’s course is set. Productivity measures are gaining traction and we’ve started the new year with good growth momentum,” said Michael Sen, Fresenius CEO.